Felodipine and renal function in lung transplantation: A randomized placebo-controlled trial

Autor: Nina Hannover Bjarnason, Karl Bang Christensen, Pia Bredahl, M. Zemtsovski, Bo Feldt-Rasmussen, Mads Hornum, Michael Perch, Jørn Carlsen, Martin Iversen, Mads J. Andersen, Peter Oturai, Christian H Møller

Publikováno v: Hornum, M, Iversen, M, Oturai, P, Andersen, M J, Zemtsovski, M, Bredahl, P, Bjarnason, N H, Christensen, K B, Carlsen, J, Møller, C H, Feldt-Rasmussen, B & Perch, M 2020, ' Felodipine and renal function in lung transplantation : A randomized placebo-controlled trial ', The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, vol. 39, no. 6, pp. 541-550 . https://doi.org/10.1016/j.healun.2020.01.1342

BACKGROUND: Calcium channel blockers may ameliorate the decline in renal function caused by calcineurin inhibitors in lung transplantation (LTX) recipients. We hypothesized that pre-operative and 12-week post-operative treatment with the calcium chan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::401b296720160f0a6ee5d2b7f0ae223c
https://doi.org/10.1016/j.healun.2020.01.1342

Raloxifene and estrogen reduces progression of advanced atherosclerosis — a study in ovariectomized, cholesterol-fed rabbits

Autor: Jens Haarbo, Raymond F. Kauffman, Inger Byrjalsen, Nina Hannover Bjarnason, Claus Christiansen, Peter Alexandersen

Publikováno v: Atherosclerosis. 154:97-102

The present study investigated the effect of raloxifene, a selective estrogen receptor modulator (SERM), on aortic atherosclerosis in 80 ovariectomized, cholesterol-fed rabbits with pre-induced atherosclerosis. The animals were fed an atherogenic die

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::574ffde891de4f25dc4859763a4c7ac5
https://doi.org/10.1016/s0021-9150(00)00470-6

Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits

Autor: Jens Haarbo, Claus Christiansen, Nina Hannover Bjarnason, Mary Pat Knadler, Inger Byrjalsen, Raymond F. Kauffman

Publikováno v: Clinical Endocrinology. 52:225-233

OBJECTIVE We have previously shown that raloxifene, a selective oestrogen receptor modulator, 35 mg/day inhibits atherosclerosis in ovariectomized, cholesterol-fed rabbits. This effect was only partial as compared to 17beta-oestradiol 4 mg/day; howev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d48ccf06c9996407498d5a41c3b2249f
https://doi.org/10.1046/j.1365-2265.2000.00919.x

[Intrathoracic goiter with differential diagnostic difficulties]

Autor: Susanne, Scherer, Dunia Gazi, Abd-Elrahmane, René Horsleben, Petersen, Nina Hannover, Bjarnason

Publikováno v: Ugeskrift for laeger. 171(3)

Intrathoracic goiter represents an important differential diagnosis in the examination of lung tumours. A 71-year-old healthy woman presented with dyspnoea, stridor and an inhomogeneous tumour compressing the upper part of the right lung at the level

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f1372e8dc1d880787b02b250cb582fa5
https://pubmed.ncbi.nlm.nih.gov/19174029

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years

Autor: Claude D. Arnaud, C. Conrad Johnston, Draper Michael William, Nina Hannover Bjarnason, Steven Watts, Timothy M. Mason, Gerald Crans, Elaine E. Jolly, Leo Plouffe, Patrick Neven, Robin Akers

Publikováno v: Menopause (New York, N.Y.). 10(4)

Raloxifene hydrochloride (60 mg/day) is a selective estrogen receptor modulator indicated for the prevention and treatment of postmenopausal osteoporosis. Raloxifene treatment for 3 years increases bone mineral density (BMD) and, unlike tamoxifen (a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f21f93cf05e1cbc5a06b188d6a926bb
https://pubmed.ncbi.nlm.nih.gov/15243288